EXEL News and Press, Exelixis Inc. From 11/01/22

Exelixis ( NASDAQ: EXEL ) has brokered collaboration deals with two companies giving the biotech the right to acquire a potential first-in-class peptide-drug conjugate and work on the development of an antibody targeting SIRPα. In its deal with Cybrexa Therapeutics ...

The following slide deck was published by Exelixis, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Exelixis, Inc. 2022 Q3 - Results - Earnings Call Presentation

Exelixis ( NASDAQ: EXEL ) saw its Q3 2022 financial results beat on the top and bottom lines while its full-year revenue estimate of $1.575B-$1.6B just included the consensus estimate of $1.6B The biotech saw its net income in the quarter surge ~92% to ~$73.2M compared to ...

Exelixis press release ( NASDAQ: EXEL ): Q3 Non-GAAP EPS of $0.31 beats by $0.07 . Revenue of $411.74M (+25.4% Y/Y) beats by $8.58M . Cash, cash equivalents, restricted cash equivalents and investments were $2.1 billion at September 30, 2022, as compared to $1....

— IND filing for ADU-1805 expected in Q1 2023, providing Exelixis with an opportunity to expand its clinical pipeline — — ADU-1805 may have broad applicability across multiple tumor types, including solid tumors — Exelixi...

– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors – – Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeut...

– Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million – – GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc....

There are pros and cons to investing in biotech stocks. One of the advantages is that shares of drugmakers can explode in a short period, especially following regulatory or clinical wins. On the other hand, the industry tends to be volatile, which may not suit some people's investment style...

– XB002, a next-generation tissue factor-targeting antibody-drug conjugate, was well-tolerated at multiple dose levels – – Pharmacokinetic analysis confirmed XB002 was stable with low levels of free payload – Exelixis, Inc. (Na...

Interest rates have been on the rise this year, and inflation still remains a big problem for the federal government. In September, the inflation rate was 8.2%, which is lower than it was in the previous month, but it's nowhere near the Fed's goal of 2%. What that tells investors is that mo...